Collaboration

T cells
#Collaboration #Evotec #Oncology #Plectonic Biotech #T cell engagers

Partners explore T cell engaging approaches for solid tumours

Evotec and Plectonic Biotech have announced a research collaboration to explore a novel immunotherapy approach for solid tumours.   The collaboration aims to address key challenges that have so far limited the successful application of traditional T cell engager therapies in solid tumours by combining Plectonic’s programmable LOGIBODY technology with Evotec’s… Read More

#Business & Investment #Cancer Research #News

Antibody-drug conjugate
#ADC #Antibodies #Antibody drug conjugate (ADC) #Cancer research #Collaboration #Gilead Sciences #Nucleai #Oncology

Nucleai and Gilead Sciences enter oncology ADC collaboration

Nucleai and Gilead Sciences have entered an ongoing translational research collaboration, supporting Nucleai’s global antibody-drug conjugate (ADC) clinical development programmes. Nucleai’s AI-powered platform analyses pathology images to provide quantitative insights into tissue biology. As part of its collaboration with Gilead, Nucleai has analysed a large dataset of hematoxylin and eosin… Read More

#News

#Autoimmune disease #Collaboration #Evotec #Inflammatory diseases #Odyssey Therapeutics

Evotec joins Odyssey in autoimmune drug development

Evotec has entered a strategic R&D collaboration with Odyssey Therapeutics to discover potential new treatments in autoimmune and inflammatory diseases.  Under the agreement, Odyssey will use Evotec's data-driven discovery platform, screening capabilities and AI-enabled data science technologies to discover and validate differentiated small molecule drug candidates across multiple high-value disease… Read More

#Business & Investment #News

Human data concept
#AI / data analytics / healthtech / informatics #Collaboration #GSK #Relation

GSK teams up with Relation to improve disease biology knowledge

Pharmaceutical company GSK has announced a strategic collaboration with the biotech Relation to improve the understanding of disease biology and support the discovery of new therapeutic targets.  Specifically, the partnership will focus on generating large-scale human cellular perturbation data and deploying them into models, such as Relation’s cellular biology foundational… Read More

#Business & Investment #News

#AI / data analytics / healthtech / informatics #CNS #Collaboration #Drug discovery

Insilico Medicine and CMS announce CNS disease collaboration 

Insilico Medicine, a clinical-stage biotechnology company driven by generative artificial intelligence (AI), and China Medical System Holdings has announced an AI‑empowered drug discovery collaboration.   The collaboration is targeting a mass-market indication in central nervous system (CNS) with an innovative mechanism of action (MoA) identified by PandaOmics. According to the collaboration agreement, the two parties will jointly advance the co-development… Read More

#News

Antibody drug conjugate
#Antibody drug conjugate (ADC) #Collaboration #Lonza

Lonza and InduPro to collaborate on next-gen ADC therapies 

Lonza and InduPro have signed a licensing agreement to advance next-generation antibody-drug conjugates (ADC) therapies.  Under the terms of the agreement, Lonza will grant InduPro a non-exclusive, worldwide license to its proprietary GlycoConnect, HydraSpace and linker-payload technologies. These technologies will be applied to the development of ADCs targeting up to two oncology antigens, supporting the… Read More

#Business & Investment #Cancer Research #News

#Collaboration #Innovent #Oncology #Pfizer

Pfizer and Innovent Biologics ink $10.5 billion oncology deal

Pfizer and Innovent Biologics have entered into a collaboration agreement for the research and development of 12 new early-stage cancer medicines, worth up to $10.5 billion.  The companies say the partnership includes licensing, co-development, and co-commercialisation opportunities across a portfolio of antibody-drug conjugates (ADCs) with differentiated payloads and multi-specific antibodies… Read More

#Business & Investment #News #Trending News

#Artificial intelligence (AI) #AstraZeneca #Collaboration #Immunai #Oncology

AstraZeneca expands AI oncology collaboration with Immunai

AstraZeneca and Immunai have expanded their collaboration, extending a multi-year collaboration in oncology clinical development through 2027.  Under the new deal, Immunai is eligible to receive up to $37.5 million over 2026-2027. It marks the third expansion of the partnership between the two companies, building on previous collaborations in oncology… Read More

#Business & Investment #News

Hepatitis B
#China #Collaboration #hepatitis

Aligos and Xiamen Amoytop agree hepatitis B alliance

Aligos Therapeutics and Xiamen Amoytop Biotech have entered into an exclusive license agreement to develop and commercialise pevifoscorvir sodium in Greater China for chronic hepatitis B virus (HBV) infection.  Under the terms of the agreement, Aligos will receive an upfront milestone of $25 million and is eligible to receive up… Read More

#Business & Investment #News

#Collaboration #Radiopharmaceuticals #Regeneron Pharmaceuticals #Telix Pharmaceuticals

Regeneron & Telix collaborate on next-gen radiopharmaceuticals

Pharmaceutical companies Regeneron and Telix have announced a collaboration to develop and commercialise next generation radiopharmaceutical therapies. The collaboration will include multiple solid tumour targets from Regeneron’s portfolio of antibodies. The companies also aim to develop radio-diagnostics to support patient selection and treatment response assessment. The deal will see Telix… Read More

#Business & Investment #News

Novo Nordisk head office
#Artificial intelligence (AI) #Collaboration #Drug discovery #Novo Nordisk #OpenAI

Novo Nordisk partners with OpenAI across operations

Novo Nordisk has announced a strategic partnership with OpenAI that it hopes will place the company at the forefront of AI transformation in healthcare and help it bring new and better treatment options to patients faster.  The partnership will apply advanced AI capabilities to analyse complex datasets, identify promising drug… Read More

#Business & Investment #News

#Cancer research #Collaboration #Organoids

Global collaboration aims to create safer cancer therapeutics 

An international collaboration is set to evaluate chemotherapeutic toxicity in human organoids, aiming to generate safer and more effective cancer therapeutics.  iXCells Biotechnologies, a provider of human cell-based solutions and iPSC services, has announced it has joined the collaboration alongside Rosebud Biosciences, Kantify and Incite. The project will… Read More

#Cancer Research #News

Roche headquarters
#Artificial intelligence (AI) #Automation / robotics #Collaboration #NVIDIA #Roche

Roche leads AI drug discovery with new NVIDIA deal

Roche now operates the pharmaceutical industry’s largest announced hybrid-cloud AI factory, totalling more than 3,500 GPUs, following an expansion of its global AI infrastructure.  The company has deployed a large-scale AI factory powered by a full stack of the latest-generation NVIDIA accelerated computing and AI, marking the next phase of… Read More

#Business & Investment #News

Heart
#Alnylam Pharmaceuticals #Cardiovascular disease #Collaboration #Tenaya Therapeutics

Alnylam and Tenaya agree cardiovascular disease collab

Alnylam Pharmaceuticals and Tenaya Therapeutics have agreed a research collaboration to discover novel human genetic targets for the potential development of disease-modifying treatments for cardiovascular diseases.  Under the terms of the agreement, Tenaya Therapeutics will validate up to 15 gene targets.   In return, Tenaya will receive up to $10 million… Read More

#Business & Investment #News

#Collaboration #Metabolic diseases #Novo Nordisk #Vivtex

Novo Nordisk and Vivtex partner on oral metabolic therapies

Novo Nordisk and Vivtex Corporation have announced a partnership to develop oral biologic medicines for obesity, diabetes and associated comorbidities.  Under the agreement, Vivtex will license select oral drug-delivery technologies to Novo Nordisk, while Vivtex is eligible to receive upfront payments totalling up to $2.1 billion, and tiered royalties on… Read More

#Business & Investment #News

Biochemists working in the lab
#Artificial intelligence (AI) #Autoimmune disease #CNS #Collaboration #Insilico Medicine

Insilico and CMS announce CNS and autoimmune collaboration

Insilico Medicine and China Medical System (CMS) have announced a series of AI‑empowered drug discovery collaborations in the fields of central nervous system and autoimmune diseases.  According to the collaboration agreement, the parties will combine Insilico Medicine's AI-enabled drug discovery and development capabilities with CMS's experienced R&D team and disease-area… Read More

#Business & Investment #News